Investment Rating - The report maintains a "Buy" rating for the company [10] Core Insights - The company reported a revenue of 13.96 billion HKD for the first half of 2025, representing a year-on-year increase of 4.4%, primarily driven by growth in the animal nutrition segment [2][6] - The net profit attributable to shareholders reached 1.79 billion HKD, a significant year-on-year increase of 72.1%, mainly due to higher gross margins in the food additives and animal nutrition divisions [2][6] - The interim dividend declared is 0.365 HKD per share, which includes basic interim dividends, special interim dividends, and tax-exempt compensation [2][6] Summary by Sections Revenue and Profitability - The company achieved a revenue of 13.96 billion HKD, with the animal nutrition segment being the key contributor [2][6] - The net profit attributable to shareholders was 1.79 billion HKD, reflecting a substantial increase due to improved gross margins [2][6] Segment Performance - The food additives segment generated revenue of 6.47 billion HKD, with a gross margin of 15.8% [8] - The animal nutrition segment reported revenue of 5.41 billion HKD, with a gross margin of 28.2% [8] - The high-end amino acids segment achieved a revenue of 1.05 billion HKD, with a gross margin of 40.7% [8] Market Dynamics - The company is a leading player in the global monosodium glutamate industry, with expectations of increased demand as the industry recovers [8] - The company is actively expanding its international presence, with new production capacities coming online and a project in Kazakhstan underway [8]